Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Feschenko, L. Iashyna, I. Iliinskaya, J. Matvienko, S. Moskalenko (Kiev, Ukraine). Immunological effectiveness of N-acetylcystein in complex therapy in severe persistent bronchial asthma patients. Eur Respir J 2008; 32: Suppl. 52, 499

Member's Comments

No comment yet.

Related content which might interest you: Immunological effectiveness of atorvastatin in complex therapy of severe persistent bronchial asthma Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009 Clinical and functional effectiveness of atorvastatin in complex therapy of severe bronchial asthma Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches Year: 2009 Combined therapy of severe osteoporosis for patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Non-drug methods in complex treatment of the severe bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 513s Year: 2002 Effectiveness of prolonged cholinolytic in complex basic therapy on the tolerability of physical load in severe bronchial asthma patients Source: Annual Congress 2008 - Markers and triggers of asthma Year: 2008 Efficacy of the long-term therapy with simbicort in children with bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 395s Year: 2005 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Influence of combined antiasthmatic basic therapy on hyperinflation in patients with severe bronchial asthma Source: Eur Respir J 2007; 30: Suppl. 51, 553s Year: 2007 The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Role of Pgp in corticosteroid sensitivity in patients with severe forms of bronchial asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Anti-IgE treatment in children with severe intrinsic asthma Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Advances of selenium add-on treatment in severe steroids-dependant bronchial asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Effectiveness of N-acetylcysteine in correction of oxidative stress in combined therapy in patients with severe bronchial asthma Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Heterogeneous response of airway eosinophilia to biologics in severe asthma patients Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021